【摘要】 目的 :探讨宫颈癌化疗前后癌组织中P 糖蛋白 (P gp)、胎盘型谷胱甘肽S 转移酶 (GST Л )及DNA拓扑酶Ⅱ (TopoⅡ )的表达及临床意义。方法 :用免疫组化S P法检测了 5 6例宫颈癌。结果 :化疗后宫颈癌组织中GST Л、P gp的表达率分别由化疗前的 5 7 14 %升高到 92 86 % ,2 8 5 7%升高到82 14 % ,而TopoⅡ在化疗后表达强度降低。化疗前GST Л的阳性率与化疗后癌组织的化疗反应呈负相关 (P <0 0 1)。结论 :GST Л、P gp及TopoⅡ的表达与宫颈癌多药耐药性相关 ,GST Л的高表达可能在宫颈癌耐药中起主导作用 ,检测宫颈癌组织中GST Л、P gp及TopoⅡ的表达有助于预测化疗效果及指导化疗用药更多还原

【Abstract】 Objective To approach GST Л,P gp and TopoⅡ expression and their clinical significance in cervical carcinoma . Methods The specimens of 56 cases of cervical carcinoma before and after chemotherapy were examined with S P immunohistochemistry.Results The total positive expression rates of GST Л and P gp in cervical carcinoma after chemotherapy were 92 86% and 82 14%,it was significantly higher than that of pretreatment (57 14%,28 57%).The staining reaction of TopoⅡ was decreased in cervical carcinoma after chemotherapy.Expression of GST Л before and after chemotherapy was negatively relative to chemotherapeutic response( P <0 01).Conclusions GST Л,P gp and TopoⅡ expression in cervical carcinoma are related to multidrug resistance.Overexpression of GST Л may be the most important factor.To detect GST Л,P gp and TopoⅡin carcinomous tissue is important for evaluating chemotherapeutic effect.更多还原